TheraCea Pharma LC

Tucson, AZ · Biotech · Private

Platform technology for efficient 18F-radiotracer synthesis via 19F/18F isotope exchange chemistry

Grants
$855K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Developing Versatile and Facile Chemical Synthesis Methodologies for Preparation of 18F-Tracers for PET Imaging$304,396
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Developing Bioconjugation and Preparation of 18F-Biomolecules for PET Imaging$256,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Development of 18F-radiotracer kits for detection of biomarkers by Positron Emission Tomography$295,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3197Nashville Clinic, LP—$800K
3198Sun Biopharma, Inc.——
3199Jortan Pharmaceuticals Inc.——
3200TheraCea Pharma LC——
3201SAHANE BIOTECH INC——
3202HISTONE THERAPEUTICS——
3203NAJIT TECHNOLOGIES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Method Of Synthesizing 18F Radiolabeled Biomolecular Agentsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.